Aktis Oncology, Inc. Common stock (AKTS)
PHARMACEUTICAL PREPARATIONS
Aktis Oncology, Inc. Common stock (AKTS) is listed on Nasdaq, where it has traded since January 9, 2026.
- Listed On
- Nasdaq
- Listed Since
- January 9, 2026
- Employees
- 79
- Market Cap
- $936M
About Aktis Oncology, Inc. Common stock
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 109 institutions reported holding AKTS, with 34.1 million shares worth $1.1 billion in aggregate. The largest reported holder was Mpm Bioimpact, with 4.8 million shares worth $155.9 million. Of the 5 largest holders listed below, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Mpm Bioimpact | 4,835,872 | $156M | Unchanged |
| Ecor1 Capital | 4,824,469 | $155M | Unchanged |
| Blue Owl Capital Holdings | 3,070,219 | $99M | Reduced 2.88% |
| T. Rowe Price | 2,814,946 | $91M | Reduced 23.67% |
| BlackRock | 2,278,358 | $73M | Added 7.87% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is AKTS?
Aktis Oncology, Inc. Common stock (AKTS) is listed on Nasdaq, where it has traded since January 9, 2026.
Who are the largest institutional holders of AKTS?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of AKTS were Mpm Bioimpact, Ecor1 Capital and Blue Owl Capital Holdings.
How many institutions own AKTS?
109 institutions reported a position in AKTS for the quarter ended June 30, 2026, worth $1.1 billion in total.
Did institutions buy or sell AKTS last quarter?
Of the 5 largest reported holders, 1 added shares, 2 reduced their positions and 2 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for AKTS.
Every reported institutional holder, plus insider and congressional trades in AKTS, on SentiSense.